Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU GMP Annex 1 Revisions Will Require Stronger Visual Inspection Programs

Executive Summary

An industry expert tells pharmaceutical manufacturers to be aware of changes proposed for Annex 1 of the European Commission's GMP guide that affect visual inspections and particulate control for new parenteral drugs. The revision calls for stricter standards for visually screening products for defects.

Advertisement

Related Content

Timeline For EU GMP Annex 1 Revision Remains Unclear

Topics

Advertisement
UsernamePublicRestriction

Register

PS125189

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel